BMO Capital analyst Matthew Luchini lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $69.00 (from $89.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Wedbush Downgrades Apellis Pharmaceuticals (APLS) to NeutralSeptember 10, 2021 7:29 AM Apellis Pharmaceuticals (APLS) PT Lowered to $65 at OppenheimerSeptember 10, 2021 6:58 AM Apellis Pharmaceuticals (APLS) PT Lowered to $70 at Needham & CompanySeptember 10, 2021 6:54 AM Apellis Pharmaceuticals (APLS) PT Lowered to $38 at Credit SuisseSeptember 10, 2021 6:09 AM After-Hours Stock Movers 09/09: (ISEE) (AFRM) (KPLT) Higher; (APLS) (COOK) (ZUMZ) Lower (more...)September 9, 2021 5:52 PM Apellis Pharmaceuticals (APLS) to Resume Trading at 4:35 p.m. September 9, 2021 4:14 PM UPDATE: IVERIC bio (ISEE) Gains Following Results From Apellis Pharmaceuticals (APLS)September 9, 2021 4:14 PM Form 8-K Apellis Pharmaceuticals, For: Sep 09September 9, 2021 4:11 PM Apellis Pharmaceuticals (APLS) Announces Results of Phase 3 DERBY and OAKS Studies in Geographic Atrophy, Plans NDASeptember 9, 2021 4:06 PM Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022September 9, 2021 4:05 PM